The U.S. Food and Drug Administration said yesterday it had closed its investigation of Mylan Inc.'s Morgantown, W.Va., generic drug plant and "plans no additional action."
The investigation was prompted by a July 26 Pittsburgh Post-Gazette story citing a Mylan internal report that said workers sidestepped computer-generated warnings about potential problems with the medications they were making. Mylan's report called the quality control breach "pervasive" and "very serious," involving "falsifying information" and "altering product." The breaches, which occurred on all three shifts at the facility, did not affect the quality of any medications, Mylan's report stated.
The problem outlined in the report involved computer alarms known as "red screens," which warn production workers that medications may fail to meet specifications for weight, thickness or hardness. If the drug deviates from specifications, patients may not receive the proper dosage.
FDA spokeswoman Judy Leon said yesterday that Mylan "appears to have conducted an adequate investigation" of the matter and that "audit trails were intact for each instance where the software was overridden by the operator."
She said Mylan had retrained operators in the proper procedures and was "working with the software company to implement a patch" to fix the problem that allowed employees to bypass the warnings.
Mylan "did not find evidence that the lack of adherence to the [standard operating procedures] resulted in an adverse impact to the affected product lots," the FDA spokeswoman said. "The agency plans no additional action."
Chairman and CEO Robert J. Coury said the FDA's action reaffirms Cecil-based Mylan's "48-year exemplary record of quality."
"Mylan's manufacturing facilities -- especially our plant in Morgantown -- have always represented the gold standard when it comes to quality," Mr. Coury said.
The statement criticized the Post-Gazette for what Mr. Coury called "a highly irresponsible and sensational newspaper article with a biased agenda."
Mylan did not respond to numerous requests for interviews or to a series of questions faxed and e-mailed to its corporate offices for the July 26 story.
The PG's article was based on Mylan's internal report, which was obtained by the newspaper. The article included comments from multiple experts, including former FDA inspectors, who reviewed the report for the newspaper.
The experts said Mylan's report described "very serious" regulatory violations that raised troubling questions about the integrity and oversight of the plant's quality control operations.
The FDA yesterday provided the newspaper with a redacted copy of its inspection report on the red screen matter but declined to answer any questions. The agency "has concluded the investigation," Ms. Leon said. The report did not refer to language Mylan used in its internal report that called the breach "pervasive" and "very serious."
According to the report, FDA investigator William A. Warnick concluded there were deviations in standard operating procedure but that Mylan had implemented corrective and preventative action. Part of his investigation included reviewing improperly handled red screens for about 20 drugs.
Mr. Warnick said in the report that Mylan was in the process of implementing a patch from LabWare, the manufacturer of the plant's computerized quality control system, to disable the function that allowed workers to improperly bypass red screens.
A call to LabWare in Wilmington, Del., was not returned.
Mr. Warnick said he confirmed through Mylan that there were "no complaints, recalls or stability failures for the [drug] lots affected by the improperly handled red screens."
According to the report, Mr. Warnick interviewed three Mylan employees who said they were unaware that production workers could override red screens and one who admitted to doing it.
One worker told the FDA that when the unauthorized practice was discovered in May, workers were required to attend a meeting at which they were told "this cannot happen under any circumstances and that it was a violation of SOPs and GMPs [good manufacturing practices]."
Another worker told the FDA that at the meeting the company "discussed what could have happened due to the unauthorized practice and the importance of it not happening again." The report did not elaborate.
In the FDA's report, Mr. Warnick said he received a call at his home Saturday, July 25, from a Mylan executive alerting him to the impending story in the Post-Gazette.
FDA officials decided Sunday to perform a "limited inspection" at the plant on Monday and that Mr. Warnick would report his findings the same day.
In his report, Mr. Warnick stated that FDA's Baltimore district office directed him to have a "closeout" meeting with Mylan on Tuesday, July 28. At that time, he told Mylan "that there were deviations" from their standard operating procedures but that no action would be taken.
Shortly after the stock market opened that morning, Mylan issued a statement that the agency had found "a minor standard operating procedures deviation," and that "the baseless accusations in the article were unfounded."
Mylan's statement, quoting Mr. Coury, calmed investors rattled by a nearly 13 percent drop in Mylan's stock price the previous day.
Mylan's announcement was followed two hours later by one from FDA assistant commissioner Steven Solomon, who said "the investigation is ongoing and the agency has formed no conclusions at this time."
The next day, FDA officials in Baltimore ordered Mr. Warnick back to the Morgantown plant to do another inspection. He examined additional information provided by Mylan and closed his investigation the following day, reaching the same conclusion.
Mylan shares rose 61 cents yesterday, to close at $14.21.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.